Approval tainted by PBAC 'No'

Otsuka owned Taiho Pharma has secured the TGA’s provisional approval for its bile duct cancer treatment Lytgobi but will now need to resubmit the drug to PBAC.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here